Activated cytotoxic T lymphocytes (CTLs) and natural killer cells contain cytoplasmic granules thought to be important for target cell killing (27) . Following effector celltarget cell contact, these cytolytic granules are exocytosed, resulting in release of the granular contents into the extracellular space between effector and target cells (36) . Purified cytolytic granules have been demonstrated to possess cytotoxic activity (13) . The contents of murine CTL granules have been extensively characterized and shown to include at least six distinct serine proteases (20) . Although the role of these proteases in cytolysis is controversial, protease inhibitors have been shown to block CTL-mediated killing in several studies (25, 30; but also see references 12, 24, and 33) .
We recently identified a hematopoietic serine protease gene cluster on chromosome 14 (11) . This locus includes the myeloid precursor-specific gene cathepsin G (CG) and the CTL-specific CSP-B gene (the human homolog of mouse CCPI/granzyme B). Expression of a third gene in this cluster, designated CGL-2 (also known as CCP-X), has been detected only in lymphokine-activated killer cells (21) .
Expression of murine CCPI mRNA has been demonstrated in concavalin A (ConA)-stimulated peripheral blood lymphocytes (PBLs), in thymocytes costimulated with ConA and interleukin 2 (IL-2), and in mixed-lymphocyte reactions (3) . When mouse spleen cells are stimulated with ConA, maximal expression of CCPI is observed after 2 to 3 days, but no detectable expression is observed during the first 24 h of treatment (19) . Human CSP-B expression has been demonstrated in IL-2-, phytohemogglutinin (PHA)-, and staphylococcal enterotoxin A-stimulated PBLs, as well as in human CTL lines (29, 32) . In addition, CSP-B mRNA has been demonstrated in the large granular lymphocytes * Corresponding author.
obtained from a patient with a large granular lymphocyte disorder having a natural killer phenotype (32) .
Several cis-acting sequences involved in constitutive or inducible T-lymphocyte-specific expression have been identified, including enhancers 3' to the CD3-e (5) and T-cell receptor a-chain (TCRa) genes (14) and upstream activating sequences 5' to the IL-2 (7) and IL-2 receptor a-chain genes (6) . Activation of CTL-specific genes during the terminal differentiation of these cells provides additional opportunities to characterize the molecular basis of the immune response.
We are interested in understanding the mechanisms underlying the differences in tissue-specific and developmental regulation of the three linked serine protease genes. In this report, we describe the regulation of the CSP-B gene in the human T-cell line PEER. We present evidence suggesting that the induction of CSP-B transcription during T-cell activation involves both 5' cis-acting sequences and the reorganization of chromatin structure.
MATERIALS AND METHODS
Tissue culture and cell treatment. Cell lines were maintained in Iscove modified Eagle medium with 5% fetal calf serum and 5% controlled process serum replacement-4 (Sigma Chemical Co.). For all experiments, PEER cells were treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) and/or N6-2-O-dibutyryladenosine 3',5'-cyclic monophosphate (bt2cAMP; Sigma) at final concentrations of 1.6 x 10-8 M and 0.5 mg/ml, respectively. PBLs were purified by Ficoll-Hypaque density gradient centrifugation followed by monocyte depletion (adherence to plastic). PBLs were cultured with 10 RNA purification and analysis. RNA was purified by a guanidinium thiocyanate miniprep procedure essentially as described previously (4) . Preparation of end-labeled probes and S1 nuclease protection analysis were performed as described previously (18) . The P-actin probe is a genomic fragment labeled at the AvaI site in exon 3. The EBER probe is a genomic fragment labeled at the internal SmaI site. For diagrams of the CSP-B, CSP-B-neo, and CG-neo probes, see Fig. 1, 6 , and 7.
Nuclear run-on analysis. Nuclear run-on experiments were performed as described previously (10 (11) with random primerlabeled probes (8) .
DNA sequencing. DNA was subcloned in pUC plasmids and sequenced on both strands by using the dideoxy-chain termination method of Sanger et al. (15) Transfector (BTX Industries, San Diego, Calif.), using discharges of 330 V at 600-,uF capacitance. Cells were harvested by centrifugation, suspended in Iscove modified Eagle medium containing serum at 1 x 106 to 2 x 106 cells per ml, and incubated for 9 h at 37°C in 5% CO2 at 100% humidity. Cells were harvested, and RNA was prepared and analyzed as described above.
Nucleotide sequence accession number. The sequence of the 5'-flanking region of the CSP-B gene from -1170 to +1 relative to the transcriptional start site has been deposited with GenBank under accession no. M38273. RESULTS CSP-B mRNA levels increase during PBL activation. Because of the extensive homology of the hematopoietic serine protease genes, we wished to develop a highly specific assay for the detection of CSP-B mRNA. Figure la demonstrates the specificity of end-labeled CG and CSP-B probes in an S1 nuclease protection assay with U937 and PHA-activated PBL RNA as the sources of CG and CSP-B mRNA, respectively (10) . Genomic CG and CSP-B fragments were end labeled at HindlIl sites in exon 5 of each gene. Correctly spliced CG mRNA protects a 139-nucleotide (nt) probe fragment derived from exon 5, whereas spliced CSP-B mRNA protects an exon 5 probe fragment of 106 nt. Each probe is protected only by spliced exon 5 mRNA from the appropriate gene, despite the 74% identity of the two genes in the region spanned by the two probes. mRNA protecting the CG probe is detected only in the U937 cell line, whereas mRNA protecting the CSP-B probe is detected only in PHA-activated PBLs. TPA treatment of U937 cells caused the level of CG mRNA to decline ( 6 h of activation (lane 3) and reaches maximal levels within 12 to 24 h (lanes 4 and 5). CSP-B mRNA levels remain high for at least 72 h (data not shown).
CSP-B mRNA levels increase in PEER cells following exposure to TPA and bt2cAMP. To begin characterizing the molecular mechanisms of CSP-B induction, we tested several T-cell lines for CSP-B inducibility with various activating reagents. PEER, HSB-2, and Jurkat cell lines were initially treated with TPA or PHA, but no CSP-B transcripts were detected. A number of y/8 TCR-expressing clones have been derived from normal human cells. Since these clones frequently exhibit cytotoxic activity (16, 26) , we chose to focus on the fy/8 TCR-expressing PEER cell line in subsequent attempts to induce CSP-B expression. The PEER cell line was further examined by using combinations of TPA, PHA, bt2cAMP, and ionomycin (data not shown). The highest levels of CSP-B mRNA were detected in PEER cells treated simultaneously with TPA and bt2cAMP. Figure 2 shows an S1 nuclease protection analysis of RNA derived from PEER cells treated for various times with TPA and bt2cAMP alone or in combination. CSP-B mRNA is detected 24 and 48 h after the addition of TPA and bt2cAMP together (Fig. 2, lanes 9 and 10) , but not when either agent is used alone (lanes 2 to 7). The level of CSP-B mRNA induced with TPA and bt2cAMP is comparable to that found in PHAactivated PBLs (compare lanes 10 and 12). However, CSP-B mRNA accumulates more slowly in TPA-bt2cAMP-treated PEER cells than in PHA-activated PBLs. To further investigate the mechanism of CSP-B mRNA up regulation, we next analyzed transcription of the CSP-B gene in PEER cells by using a nuclear run-on assay (Fig. 3) .
PEER cell nuclei were isolated and incubated in the presence of [ot-32P]GTP. RNA was subsequently purified and hybridized with identical filters containing denatured plasmid DNA targets. Both CSP-B cDNA and genomic DNA targets were used in these experiments to control for possible cross-hybridization of related serine protease transcripts. The genomic fragment is 0.9 kb long and extends from an EcoRI site in intron 1 to an EcoRI site in intron 2 scripts are not spliced, the equivalent levels of hybridization to the cDNA and genomic target indicate that only CSP-B transcripts are detected with this assay. Figure 3A shows nuclear run-on analyses of PEER cells treated with TPA or bt2cAMP alone or in combination for 48 h. TPA and bt2cAMP are both required for the transcriptional activation of CSP-B. Hybridization with an Alu repetitive sequence or P-actin cDNA demonstrates that equivalent amounts of labeled RNA were hybridized with each filter. Figure 3B shows the time course of transcriptional activation. A low level of CSP-B transcription is detected after 24 (14) is found upstream of the CSP-B promoter at position -276. A sequence found twice in the first 300 bp 5' of the IL-2 gene (GAGGAAA) (7) is present at -1130, -1107, -44, and -12. An AP-2 consensus element (CCCCAGGC) (28) (1) (TCR,) is located at position -69. We also compared the 5'-flanking sequences of the CSP-B and murine CCPI genes (19) . Figure 5 shows a dot matrix alignment of these sequences, with dashes indicating regions with .9 of 10 matches. The upstream promoter sequences are strikingly similar from the transcriptional start site to position -600 for CSP-B and to -470 for CCPI. More distal sequences show little or no conservation. We next examined the promoter specificity of the CSP-B regulatory elements by linking these sequences with a heterologous promoter. A CSP-B fragment extending from -615 to -63 was cloned in either orientation upstream of a minimal CG promoter (extending from -76 to +23) linked to neo. Figure 7A of the minimal CG promoter results in undetectable levels of CG-neo mRNA in untreated or treated cells (Fig. 7B, lanes 2  and 6, respectively) 8) , respectively). This orientation specificity suggests that the activating sequence in the region of CSP-B from -615 to -63 behaves as an upstream activating element rather than a classical enhancer. DISCUSSION The synthesis of cytolytic granules during CTL activation requires the induction of genes encoding granule components during the activation process. In this report, we have characterized a model system for studying the transcriptional activation of the CTL-specific serine protease gene CSP-B. TPA and bt2cAMP act synergistically to activate CSP-B transcription in PEER cells. The relatively slow induction of CSP-B appears to be a multistep process involving changes in chromatin structure and promoter activation, which may require specific trans-acting factors that interact with sequences upstream from the CSP-B gene.
CSP-B mRNA accumulates in human PBLs treated with PHA. Within this heterogeneous cell population, CSP-B transcripts are detected 6 h after the addition of PHA, and maximal levels are present after 12 h. This result stands in contrast to the time course of murine CCPI induction by ConA plus IL-2 in mouse splenic T lymphocytes (19) . In this case, CCPI transcription is not detected until 24 h after addition of ConA and IL-2 and mRNA levels peak 2 days after addition. Since CSP-B mRNA is present at similar levels in human CTLs, lymphokine-activated killer cells, and natural killer cells (Heusel et al., in preparation), the time course of CSP-B mRNA accumulation in a total PBL population may represent an average of different activation kinetics in the mixed population of cells. Alternatively, fundamental differences between the activation processes of human and mouse T cells may exist.
CSP-B mRNA levels increase in PEER cells treated with both TPA and bt2cAMP. Induction of CSP-B is due to transcriptional activation, as demonstrated by nuclear run-on analyses. The transcriptional activation of the CSP-B gene requires TPA and bt2cAMP in combination, suggesting that distinct signal transduction pathways converge to regulate CSP-B expression. The relatively slow induction of CSP-B in PEER cells and the synergistic effects of TPA and bt2cAMP suggest that multiple steps may be involved in the activation process. TPA and bt2cAMP may separately direct distinct events that are necessary but not sufficient for CSP-B expression. For example, chromatin reorganization and transcription factor activation may be regulated by separate pathways. The slow induction of CSP-B could also be due to a rate-limiting cell cycle-restricted event. Preliminary experiments with aphidicolin-synchronized PEER cells suggest that the rate-limiting step in CSP-B activation is S-phase restricted. We are currently investigating the significance of this observation with respect to the mechanism of CSP-B induction.
The time course of CSP-B activation in PEER cells is very similar to that of the CCPI induction in lectin-stimulated T-lymphocytes. TCR stimulation results in protein kinase C activation, which can be simulated in vitro by the phorbol ester TPA (34) . Additional signaling events are also required for terminal CTL differentiation (34) . Fluctuations in intracellular cAMP levels have been shown to occur during T-cell activation (35) . IL-1 has been suggested to participate in primary T-cell activation in vivo (reviewed in reference 23), and an increase in intracellular cAMP levels has been demonstrated in cell lines exposed to IL-1 (reviewed in reference 22). The induction of CSP-B mRNA in TPAbt2cAMP-treated PEER cells may therefore provide a physiologic model for at least part of the CTL maturation process.
Actively expressed and inducible genes have been shown to be in a DNase I-sensitive chromatin conformation in vivo and frequently contain DNase I-hypersensitive regions (reviewed in reference 9) . Surprisingly, the CSP-B promoter is inaccessible to DNase I in untreated PEER cells, suggesting that it may be in a closed chromatin conformation, sequestered from transcription factors. However, the 5' CSP-B fragment becomes much more sensitive to DNase I following TPA-bt2cAMP treatment, and a hypersensitive site is detected exclusively in the activated cells. The inducible hypersensitive site and the extensive homology between the murine CCPI gene and the human CSP-B gene in the first 600 bp of 5'-flanking sequence suggested that important regulatory elements might be located in this region.
Analysis We are now further localizing the regulatory elements in the CSP-B 5'-flanking region so that we can characterize the transcription factors that bind to them. We are also initiating studies with transgenic mice to define the cis-acting DNA elements necessary for tissue-and development-specific expression of CSP-B. The ability to target expression to CTLs will ultimately allow us to express other gene products (such as toxic proteins or seine protease inhibitors) in these cells. Activated T-cells derived from these mice will serve as tools for further analysis of cytolytic T-cell functions. 
